Holen Sie sich die Stockscreener-App
0.9905
7.43%
-0.0795
Handel nachbörslich:
.98
-0.0105
-1.06%
Schlusskurs vom Vortag:
$1.07
Offen:
$0.9695
24-Stunden-Volumen:
270.67K
Relative Volume:
0.88
Marktkapitalisierung:
$29.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-1.6955
EPS:
-0.5842
Netto-Cashflow:
-
1W Leistung:
+5.60%
1M Leistung:
+18.13%
6M Leistung:
-49.97%
1J Leistung:
-4.30%
1-Tages-Spanne:
$0.91
$1.03
1-Wochen-Bereich:
$0.91
$1.10
52-Wochen-Spanne:
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie NRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.9905 | 31.78M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
Earnings Recap: Will NeuroSense Therapeutics Ltd Equity Warrant stock go up in YEARJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
RSI Check: Why NeuroSense Therapeutics Ltd stock appeals to analysts2025 Breakouts & Breakdowns & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Bear Alert: Can NeuroSense Therapeutics Ltd stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Momentum Picks - Bộ Nội Vụ
Risk Hedge: Is NeuroSense Therapeutics Ltd stock a good choice for value investorsJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Bộ Nội Vụ
How NeuroSense Therapeutics Ltd. stock benefits from tech adoptionEarnings Recap Summary & Verified Entry Point Signals - Улправда
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsProfit Target & Weekly High Return Stock Forecasts - Улправда
Will NeuroSense Therapeutics Ltd. stock remain a Wall Street favorite2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Technical Analysis: What risks investors should watch in NeuroSense Therapeutics Ltd stockRate Cut & Verified Stock Trade Ideas - Bộ Nội Vụ
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Sahm
What risks investors should watch in NeuroSense Therapeutics Ltd. stockForecast Cut & Precise Swing Trade Entry Alerts - ulpravda.ru
Is NeuroSense Therapeutics Ltd. stock resilient to inflationGlobal Markets & Weekly High Momentum Picks - Улправда
Will NeuroSense Therapeutics Ltd. Equity Warrant stock recover faster than peersJuly 2025 WrapUp & Weekly Market Pulse Updates - Улправда
NeuroSense Therapeutics Ltd.Ordinary Shares (NQ: NRSN - FinancialContent
How NeuroSense Therapeutics Ltd. Equity Warrant stock responds to policy changesWeekly Risk Summary & Weekly High Potential Alerts - Улправда
Can NeuroSense Therapeutics Ltd. stock resist sector downturnsWeekly Investment Recap & High Return Stock Watch Alerts - Улправда
Trading Recap: Will NeuroSense Therapeutics Ltd. (H1Z) stock justify high valuation2025 Price Momentum & Fast Gain Stock Tips - Улправда
Can NeuroSense Therapeutics Ltd. stock continue upward trendBreakout Watch & Free AI Powered Buy and Sell Recommendations - Улправда
Is NeuroSense Therapeutics Ltd. Equity Warrant stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
NeuroSense Therapeutics Ltd. Appoints Prof. Steven E. Arnold to Scientific Advisory Board - MarketScreener
Hedge Fund Bets: How NeuroSense Therapeutics Ltd. Equity Warrant stock performs after earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
How NeuroSense Therapeutics Ltd. stock compares to growth peers2026 world cup usa national team semifinals defensive leaders set piece tactics match prediction analysis - ulpravda.ru
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - Sahm
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's - Nasdaq
NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial - TipRanks
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile By Investing.com - Investing.com South Africa
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile - Investing.com
Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan
Rally Mode: Is Capella Minerals Limited (N7D) stock worth buying before Fed actionEarnings Overview Summary & Safe Capital Investment Plans - moha.gov.vn
Will NeuroSense Therapeutics Ltd. stock pay special dividends2025 Volume Leaders & Verified Swing Trading Watchlists - Улправда
ETF Watch: Can NeuroSense Therapeutics Ltd. (H1Z) stock sustain institutional flowsJuly 2025 Recap & Fast Gain Swing Trade Alerts - DonanımHaber
How NeuroSense Therapeutics Ltd. (H1Z) stock compares with tech leaders2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
It had formed inverted head and shoulders earlier soon it gave a break out of the pattern.2025 Historical Comparison & High Conviction Buy Zone Alerts - Bollywood Helpline
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requi - GuruFocus
Whale Trades: What dividend safety rating applies to NeuroSense Therapeutics Ltd H1Z stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - MSN
Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com
NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView — Track All Markets
NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView — Track All Markets
NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):